Research programme: COVID-19 therapeutic antibodies - AcadeMab Biomedical
Latest Information Update: 24 Dec 2022
At a glance
- Originator AcadeMab Biomedical
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research COVID 2019 infections
Most Recent Events
- 07 Dec 2022 COVID-19 therapeutic antibodies - AcadeMab Biomedical is available for licensing as of 13 Jul 2022
- 30 Nov 2022 Pharmacodynamics data from early research in COVID-2019 infections released by AcadeMab Biomedical (AcadeMab Biomedical pipeline, November 2022)
- 13 Jul 2022 Early research in COVID-2019 infections in Taiwan (Parenteral) before July 2022